Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenaya TherapeuticsTNYA -3.04%32 3-Year ROIIC % is -70.78 as of Dec. 2025. GuruFocus rates TNYA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,315 Biotechnology companies, Tenaya Therapeutics ranks worse than 69.28% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Tenaya Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -70.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Tenaya Therapeutics's 3-Year ROIIC % or its related term are showing as below:
TNYA's 3-Year ROIIC % is ranked worse than 69.28% of 1315
companies
in the Biotechnology industry
Industry Median: -4.4
vs TNYA: -70.78
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tenaya Therapeutics 3-Year ROIIC % Related Terms
Tenaya Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Tenaya Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNYA vs KPTI, HUMA, CRBP: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Tenaya Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenaya Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's 3-Year ROIIC % falls into.
Tenaya Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -93.331 (Dec. 2025) - -125.621 (Dec. 2022) )
/
( 50.544 (Dec. 2025) - 96.165 (Dec. 2022) )
=
32.29
/
-45.621
=
-70.78%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tenaya Therapeutics (TNYA) has a 3-Year ROIIC % of -70.78 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tenaya Therapeutics and its competitors. According to the industry distribution chart, Tenaya Therapeutics ranks #911 out of 1315 companies in the Biotechnology industry, placing it in the top 69.3%.
Is Tenaya Therapeutics' 3-Year ROIIC % too high?
Tenaya Therapeutics' current 3-Year ROIIC % is -70.78. Based on the distribution chart, Tenaya Therapeutics ranks #911 out of 1315 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tenaya Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' 3-Year ROIIC % compare to KPTI and HUMA?
According to the Biotechnology industry distribution chart, Tenaya Therapeutics ranks #911 out of 1315 companies for 3-Year ROIIC %. This places Tenaya Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tenaya Therapeutics and its competitors. Tenaya Therapeutics's current 3-Year ROIIC % is -70.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current 3-Year ROIIC % of -70.78. The current 3-Year ROIIC % is -70.78. Tenaya Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current 3-Year ROIIC % is -70.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score
Get the complete analysis for TNYA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNYA has been successfully added to your 
